CAR-T Therapy Global Market Report 2024

Chimeric Antigen Receptor-T (CAR-T) therapy is a form of immunotherapy where T-cells are extracted from the patient's blood, genetically modified in a lab by adding a specialized protein receptor (CAR), enabling the T-cells to recognize and eliminate cancer cells. These modified cells are then infused back into the patient, acting as living drugs in the body.

The primary types of CAR-T therapy are monotherapy and combination therapy. Monotherapy involves treating a disease with a single drug. The targeted antigens include CD19, CD22, and others, applied in various medical conditions such as acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, multiple myeloma, among others.

The chimeric antigen receptor -T therapy market research report is one of a series of new reports from The Business Research Company that provides chimeric antigen receptor -T therapy market statistics, including chimeric antigen receptor -T therapy industry global market size, regional shares, competitors with a chimeric antigen receptor -T therapy market share, detailed chimeric antigen receptor -T therapy market segments, market trends and opportunities, and any further data you may need to thrive in the chimeric antigen receptor -T therapy industry. This chimeric antigen receptor -T therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The car-t therapy market size has grown rapidly in recent years. It will grow from $2.15 billion in 2023 to $2.55 billion in 2024 at a compound annual growth rate (CAGR) of 19.1%. The historical growth can be attributed to the rise in healthcare expenditure, increased pharmaceutical research and development (R&D) spending, and advancements in drug discovery.

The car-t therapy market size is expected to see rapid growth in the next few years. It will grow to $4.74 billion in 2028 at a compound annual growth rate (CAGR) of 16.7%. Forecasted growth is fueled by an increase in blood cancer incidence rates, higher healthcare expenditure, a robust drug pipeline, and a heightened focus on CAR-T therapy. Key trends include R&D investments for redesigned CAR-T therapy, developing off-the-shelf allogeneic CAR-T treatment, manufacturing next-gen CAR-T cells, utilizing AI for optimization, strategic collaborations, and acquisitions to expand CAR-T therapy portfolios.

The growth of the CAR-T therapy market is significantly influenced by increased financial support from diverse organizations aimed at fostering the development and utilization of CAR-T therapy. Governmental and non-governmental bodies extend financial aid to companies operating within the CAR-T therapy market, facilitating research and development initiatives as well as aiding patients seeking treatment for acute lymphoblastic leukemia (ALL). An illustration of such support can be observed in December 2021 when the University of California San Diego School of Medicine received a substantial funding grant of US$ 4.1 million from the California Institute for Regenerative Medicine (CIRM). This grant specifically aimed at advancing the development of innovative chimeric antigen receptor (CAR-T) cell therapy. The backing provided by various organizations toward CAR-T therapy acts as a driving force propelling the market's growth.

The escalating prevalence of cancer globally stands as a pivotal factor propelling the expansion of the CAR-T therapy market. The rising incidence of cancer signifies an increased number of diagnosed cases within specific populations or regions over defined periods. This surge in cancer prevalence has spurred extensive research endeavors and investments in cancer therapies, notably cellular immunotherapies such as CAR-T therapy. These therapies mark a significant stride in oncological advancements, addressing the critical needs of cancer patients. For instance, statistics from the American Cancer Society in 2021 projected staggering figures of new cancer cases and deaths (1.9 million new cases and 608,570 deaths) anticipated in the United States that year. Hence, the mounting prevalence of cancer serves as a primary driver propelling the growth trajectory of the CAR-T therapy market.

Companies within the CAR-T therapy market are actively engaged in clinical trials aimed at assessing the efficacy of CAR-T therapy in treating multiple myeloma, a form of cancer characterized by the accumulation of cancerous cells in the bone marrow, often encroaching upon healthy blood cells. CAR-T therapy represents a potential treatment for relapsed or refractory multiple myeloma (RRMM), with CAR-T cells engineered to target the specific cells responsible for the disease. An example of this advancement can be seen in December 2021, with Novartis unveiling T-Charge, its next-generation CAR-T platform designed as a foundational framework for various new investigational CAR-T cell therapies within the Novartis pipeline. This product was in the early clinical stage (Phase I), indicating ongoing efforts to explore its potential in treating multiple myeloma.

Major companies operating in the CAR-T cell therapies market are dedicated to innovating new products such as BioCentriq to augment their profitability within the industry. BioCentriq serves as a valuable resource for organizations involved in the realm of cell and gene therapies, facilitating advancements in development, manufacturing, and research efforts, ultimately aiming to enhance patient care. For instance, in October 2023, Terumo Blood and Cell Technologies, a Japanese medical technology company, introduced BioCentriq with the objective of generating accessible public data concerning CAR-T cell manufacturing using Terumo BCT's CGT (Cell and Gene Therapy) manufacturing platforms. In collaboration with Terumo BCT, BioCentriq strives to pioneer publicly available data focusing on swift CAR-T cell manufacturing, employing the Quantum Flex and Finia platforms. This innovative trial aims to demonstrate the efficient production of high-quality CAR-T cells, leveraging the seamless integration of Terumo BCT's technology and BioCentriq's process expertise to establish streamlined, GMP-translatable workflows.

In July 2023, Astellas Pharma Inc., a Japanese pharmaceutical company, successfully acquired Iveric Bio for $5.9 billion. This strategic move enhances Astellas' ability to address patients at high risk of vision loss due to ocular illnesses. The acquisition leverages Iveric Bio's expertise in ophthalmology alongside Astellas' global resources, aiming to create a leading organization in the field. The transaction was subject to standard closing requirements, including approval from Iveric Bio's stockholders and regulatory approvals. Iveric Bio is a U.S.-based biotech company.

Major companies operating in the car-t therapy market report are Gilead Sciences, Novartis AG, Biocon, Gracell Biotechnology Ltd., Aeon Therapeutics, CARsgen Therapeutics, Daiichi Sankyo, Otsuka Pharmaceutical, Ono Pharmaceutical, Japan Tissue Engineering, Nipro Corporation, Takeda Pharmaceutical Company, Astellas Pharma, Innovative Cellular Therapeutics, Cellular Biomedicine Group, PersonGen Biomedicine, Hebei Senlang Biotech, Adaptimmune(UK), Autolus Therapeutics, BioNTech, Cellectis, Celyad, Crescendo Biologics, GammaDelta Therapeutics, Immatics, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen, AstraZeneca, Bayer AG, Merck, Pfizer, Juno Therapeutics, Allogene Therapeutics, Bluebird Bio Amgen, Regen BioPharma, OncoSec Medical Incorporated, Precision BioSciences, Bellicum, Sandoz AG, GlaxoSmithKline PLC, Elekta, SudairPharma, Janssen, Aspen, Adcock Ingram

North America was the largest region in the CAR-t therapy market in 2023. Western Europe was the second-largest region in the global CAR-T therapy market share. The regions covered in the car-t therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the car-t therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The chimeric antigen receptor -T therapy market includes revenues earned by CAR-T therapy products and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

CAR-T Therapy Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on CAR-T therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for CAR-T therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The CAR-T therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Monotherapy; Combination Therapy
• 2) By Target Antigen: CD19; CD22; BCMA; Other Target Antigens
• 3) By Application: Acute Lymphoblastic Leukemia; Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Chronic Lymphocytic Leukemia; Multiple Myeloma; Other Applications
• Companies Mentioned: Gilead Sciences; Novartis AG; Biocon; Gracell Biotechnology Ltd; Aeon Therapeutics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.